Top

European Journal of Nutrition

Published in:

Open Access 01-08-2012 | Review

The role of adipokines in connective tissue diseases

Authors: Robert Krysiak, Gabriela Handzlik-Orlik, Boguslaw Okopien

Published in: European Journal of Nutrition | Issue 5/2012

Abstract

Objective

To discuss the relationship between adipokines and connective tissue diseases, by putting special emphasis on the potential role of leptin, adiponectin, resistin, and other adipose tissue products in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus and on possible application of adipokine-targeted therapy in the treatment of these disorders with emphasis on the recent findings.

Methods

PubMed literature search complemented by review of bibliographies listed in identified articles.

Results

Most of the data presented by different research groups showed changed levels of leptin, adiponectin, and resistin and occasionally also other adpokines in rheumatoid arthritis and systemic lupus erythematosus. The relationship between the remaining connective tissue diseases and adipokines is less documented.

Conclusions

Plasma levels of adipokines might tell us too little about their role in connective tissue disorders, whereas adipokine effects on synovial tissues might differ from their known metabolic or cardiovascular effects, which implies that some re-appraisal of adipokines role may need to take place. It still remains obscure whether the observed disturbances in various adipokine systems in subjects with connective tissue diseases contribute to their development or only reflect the presence or activity of inflammatory process, which itself is induced by other pro-inflammatory factors.

Greenberg AS, Obin MS (2006) Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 83:461–465

Toussirot E, Streit G, Wendling D (2007) The contribution of adipose tissue and adipokines to inflammation in joint diseases. Curr Med Chem 14:1095–1100CrossRef

Walsmith J, Roubenoff R (2002) Cachexia in rheumatoid arthritis. Int J Cardiol 85:89–99CrossRef

Westhoff G, Rau R, Zink A (2007) Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthr Rheum 56:3575–3582CrossRef

Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM (2005) Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthr Rheum 52:3651–3659CrossRef

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432CrossRef

Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gómez-Reino JJ et al (2005) Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 579:295–301CrossRef

Yu WH, Kimura M, Walczewska A, Karanth S, McCann SM (1997) Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci USA 94:1023–1028CrossRef

Bennett BD, Solar GP, Yuan JQ, Mathias J, Thomas GR, Matthews W (1996) A role for leptin and its cognate receptor in hematopoiesis. Curr Biol 6:1170–1180CrossRef

10.

Bouloumié A, Drexler HC, Lafontan M, Busse R (1998) Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 83:1059–1066CrossRef

11.

Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI (1998) Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394:897–901CrossRef

12.

Lago F, Dieguez C, Gómez-Reino J, Gualillo O (2007) The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 18:313–325CrossRef

13.

Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ et al (1998) Leptin regulates proinflammatory immune responses. FASEB J 12:57–65

14.

Otero M, Gomez Reino JJ, Gualillo O (2003) Synergistic induction of nitric oxide synthase type II: in vitro effect of leptin and interferon-gamma in human chondrocytes and ATDC5 chondrogenic cells. Arthr Rheum 48:404–409CrossRef

15.

Krysiak R, Okopień B, Herman ZS (2005) Adipose tissue: a new endocrine organ. Przegl Lek 62:919–923

16.

Castracane VD, Kraemer RR, Franken MA, Kraemer GR, Gimpel T (1998) Serum leptin concentration in women: effect of age, obesity, and estrogen administration. Fertil Steril 70:472–477CrossRef

17.

Howard JK, Lord GM, Matarese G, Vendetti S, Ghatei MA, Ritter MA et al (1999) Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest 104:1051–1059CrossRef

18.

Faggioni R, Feingold KR, Grunfeld C (2001) Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 15:2565–2571CrossRef

19.

Garaulet M, Hernández-Morante JJ, de Heredia FP, Tébar FJ (2007) Adiponectin, the controversial hormone. Public Health Nutr 10:1145–1150CrossRef

20.

Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, Hada Y, Uchida S, Tsuchida A, Takekawa S, Kadowaki T (2005) Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 146:790–796CrossRef

21.

Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115:911–919CrossRef

22.

Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH et al (2007) Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 49:1455–1461CrossRef

23.

Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P (2006) Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 110:267–278CrossRef

24.

Fantuzzi G (2008) Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 121:326–330CrossRef

25.

Ouchi N, Walsh K (2007) Adiponectin as an anti-inflammatory factor. Clin Chim Acta 380:24–30CrossRef

26.

Guerre-Millo M (2008) Adiponectin: an update. Diabetes Metab 34:12–18CrossRef

27.

Steffens S, Mach F (2008) Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. Circ Res 102:140–142CrossRef

28.

Haugen F, Drevon CA (2007) Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 148:5478–5486CrossRef

29.

Tang CH, Chiu YC, Tan TW, Yang RS, Fu WM (2007) Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. J Immunol 179:5483–5492

30.

Song H, Chan J, Rovin BH (2009) Induction of chemokine expression by adiponectin in vitro is isoform dependent. Transl Res 154:18–26CrossRef

31.

Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, Aso Y, Inukai T, Okuno T, Node K (2007) High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 100:569–574CrossRef

32.

Baessler A, Schlossbauer S, Stark K, Strack C, Riegger G, Schunkert H, Hengstenberg C, Fischer M (2011) Adiponectin multimeric forms but not total adiponectin levels are associated with myocardial infarction in non-diabetic men. J Atheroscler Thromb 18:616–627CrossRef

33.

Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312CrossRef

34.

Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A (2005) Resistin, an adipokine with potent proinflammatory properties. J Immunol 174:5789–5795

35.

Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV et al (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50:2199–2202CrossRef

36.

Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C et al (2003) Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300:472–476CrossRef

37.

Ghosh S, Singh AK, Aruna B, Mukhopadhyay S, Ehtesham NZ (2003) The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene 305:27–34CrossRef

38.

Steppan CM, Lazar MA (2004) The current biology of resistin. J Intern Med 255:439–447CrossRef

39.

Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL (2007) Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 156:279–284CrossRef

40.

Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R et al (2003) Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 88:5452–5455CrossRef

41.

Farvid MS, Ng TW, Chan DC, Barrett PH, Watts GF (2005) Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes Obes Metab 7:406–413CrossRef

42.

Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S et al (2005) Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 48:2330–2333CrossRef

43.

Yaturu S, Reddy RD, Rains J, Jain SK (2007) Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine 37:1–5CrossRef

44.

Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA (2006) Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 12:100–105CrossRef

45.

Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J et al (2007) Serum resistin is associated with high risk in patients with congestive heart failure—a novel link between metabolic signals and heart failure. Circ J 71:460–464CrossRef

46.

Nagaev I, Bokarewa M, Tarkowski A, Smith U (2006) Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS ONE 1:E31CrossRef

47.

Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR (2003) Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 309:286–290CrossRef

48.

Senolt L, Polanska M, Filkova M, Oslejskova L, Pavelka K, Gay S et al (2010) Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann Rheum Dis 69:1410–1411CrossRef

49.

Gualillo O, González-Juanatey JR, Lago F (2007) The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 17:275–283CrossRef

50.

Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G et al (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148:4687–4694CrossRef

51.

Kralisch S, Weise S, Sommer G, Lipfert J, Lossner U, Bluher M et al (2009) Interleukin-1beta induces the novel adipokine chemerin in adipocytes in vitro. Regul Pept 154:102–106CrossRef

52.

Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Lago F, Gualillo O (2011) What’s new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 7:528–536CrossRef

53.

Conde J, Gomez R, Bianco G, Scotece M, Lear P, Dieguez C et al (2011) Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. Ann Rheum Dis 70:551–559CrossRef

54.

Sommer G, Weise S, Kralisch S, Scherer PE, Lössner U, Blüher M et al (2008) The adipokine SAA3 is induced by interleukin-1beta in mouse adipocytes. J Cell Biochem 104:2241–2247CrossRef

55.

Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118:3537–3545CrossRef

56.

Kaplan MJ (2006) Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 18:289–297CrossRef

57.

Schulze-Koops H, Kalden JR (2001) The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 15:677–691CrossRef

58.

Busso N, So A, Chobaz-Péclat V, Morard C, Martinez-Soria E, Talabot-Ayer D et al (2002) Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J Immunol 168:875–882

59.

Otero M, Lago R, Lago F, Reino JJ, Gualillo O (2005) Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1. Arthr Res Ther 7:R581–R591CrossRef

60.

Gualillo O (2007) Further evidence for leptin involvement in cartilage homeostases. Osteoarthr Cartil 15:857–860CrossRef

61.

Hultgren OH, Tarkowski A (2001) Leptin in septic arthritis: decreased levels during infection and amelioration of disease activity upon its administration. Arthr Res 3:389–394CrossRef

62.

Palmer G, Gabay C (2003) A role for leptin in rheumatic diseases? Ann Rheum Dis 62:913–915CrossRef

63.

Seven A, Güzel S, Aslan M, Hamuryudan V (2009) Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis. Rheumatol Int 29:743–747CrossRef

64.

Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gómez-Reino JJ et al (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65:1198–1201CrossRef

65.

Targońska-Stepniak B, Majdan M, Dryglewska M (2008) Leptin serum levels in rheumatoid arthritis patients: relation to disease duration and activity. Rheumatol Int 28:585–591CrossRef

66.

Bokarewa M, Bokarew D, Hultgren O, Tarkowski A (2003) Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 62:952–956CrossRef

67.

Anders HJ, Rihl M, Heufelder A, Loch O, Schattenkirchner M (1999) Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. Metabolism 48:745–748CrossRef

68.

Fraser DA, Thoen J, Bondhus S, Haugen M, Reseland JE, Djøseland O et al (2000) Reduction in serum leptin and IGF-1 but preserved T-lymphocyte numbers and activation after a ketogenic diet in rheumatoid arthritis patients. Clin Exp Rheumatol 18:209–214

69.

Ahima RS (2000) Leptin and the neuroendocrinology of fasting. Front Horm Res 26:42–56CrossRef

70.

Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW (2005) Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 64:1195–1198CrossRef

71.

Schäffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Schölmerich J et al (2003) Adipocytokines in synovial fluid. JAMA 290:1709–1710CrossRef

72.

Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA et al (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35:842–849CrossRef

73.

Senolt L, Pavelka K, Housa D, Haluzík M (2006) Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 35:247–252CrossRef

74.

Ehling A, Schäffler A, Herfarth H, Tarner IH, Anders S, Distler O et al (2006) The potential of adiponectin in driving arthritis. J Immunol 176:4468–4478

75.

Westra J, Limburg PC, de Boer P, van Rijswijk MH (2004) Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis 63:1453–1459CrossRef

76.

Kitahara K, Kusunoki N, Kakiuchi T, Suguro T, Kawai S (2009) Adiponectin stimulates IL-8 production by rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 378:218–223CrossRef

77.

Gómez R, Scotece M, Conde J, Gómez-Reino JJ, Lago F, Gualillo O (2011) Adiponectin and leptin increase IL-8 production in human chondrocytes. Ann Rheum Dis 70:2052–2054CrossRef

78.

Lago R, Gomez R, Otero M, Lago F, Gallego R, Dieguez C et al (2008) A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthr Cartil 16:1101–1109CrossRef

79.

Tan W, Wang F, Zhang M, Guo D, Zhang Q, He S (2009) High adiponectin and adiponectin receptor 1 expression in synovial fluids and synovial tissues of patients with rheumatoid arthritis. Semin Arthr Rheum 38:420–427CrossRef

80.

Kobashi C, Urakaze M, Kishida M, Kibayashi E, Kobayashi H, Kihara S et al (2005) Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 97:1245–1252CrossRef

81.

Kusunoki N, Kitahara K, Kojima F, Tanaka N, Kaneko K, Endo H et al (2010) Adiponectin stimulates prostaglandin E(2) production in rheumatoid synovial fibroblasts. Arthr Rheum 62:1641–1649CrossRef

82.

Rovin BH, Song H (2006) Chemokine induction by the adipocyte-derived cytokine adiponectin. Clin Immunol 120:99–105CrossRef

83.

Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V et al (2006) Peripheral factors in the metabolic syndrome: the pivotal role of adiponectin. Ann NY Acad Sci 1083:185–195CrossRef

84.

Behre CJ (2008) Adiponectin: a defense protein in catabolism. J Allergy Clin Immunol 122:1236CrossRef

85.

Ebina K, Fukuhara A, Ando W, Hirao M, Koga T, Oshima K et al (2009) Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin Rheumatol 28:445–451CrossRef

86.

Venkatesh B, Hickman I, Nisbet J, Cohen J, Prins J (2009) Changes in serum adiponectin concentrations in critical illness: a preliminary investigation. Crit Care 13:R105CrossRef

87.

Giles JT, van der Heijde DM, Bathon JM (2011) Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis 70:1562–1568CrossRef

88.

Giles JT, Allison M, Bingham CO III, Scott WM Jr, Bathon JM (2009) Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthr Rheum 61:1248–1256CrossRef

89.

Klein-Wieringa IR, van der Linden MP, Knevel R, Kwekkeboom JC, van Beelen E, Huizinga TW et al (2011) Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthr Rheum 63:2567–2574CrossRef

90.

Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD et al (2006) Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 21:1648–1656CrossRef

91.

Lee SW, Kim JH, Park MC, Park YB, Lee SK (2008) Adiponectin mitigates the severity of arthritis in mice with collagen-induced arthritis. Scand J Rheumatol 37:260–268CrossRef

92.

Chedid P, Hurtado-Nedelec M, Marion-Gaber B, Bournier O, Hayem G, Gougerot-Pocidalo MA et al (2012) Adiponectin and its globular fragment differentially modulate the oxidative burst of primary human phagocytes. Am J Pathol 180:682–692CrossRef

93.

Migita K, Maeda Y, Miyashita T, Kimura H, Nakamura M, Ishibashi H et al (2006) The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 24:698–701

94.

Forsblad d’Elia H, Pullerits R, Carlsten H, Bokarewa M (2008) Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) 47:1082–1087CrossRef

95.

Brugos B, Kiss E, Dul C, Gubisch W, Szegedi G, Sipka S, Zeher M (2010) Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. Hum Immunol 71:874–877CrossRef

96.

Straburzyńska-Lupa A, Nowak A, Pilaczyńska-Szcześniak Ł, Straburzyńska-Migaj E, Romanowski W, Karolkiewicz J et al (2010) Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis. Clin Exp Rheumatol 28:19–24

97.

Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H et al (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178:1748–1758

98.

Ozgen M, Koca SS, Dagli N, Balin M, Ustundag B, Isik A (2010) Serum adiponectin and vaspin levels in rheumatoid arthritis. Arch Med Res 41:457–463CrossRef

99.

Eisinger K, Bauer S, Schäffler A, Walter R, Neumann E, Buechler C, Müller-Ladner U, Frommer KW (2012) Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis. Exp Mol Pathol 92:90–96CrossRef

100.

Gupta K, Shukla M, Cowland JB, Malemud CJ, Haqqi TM (2007) Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthr Rheum 56:3326–3335CrossRef

101.

Vallon R, Freuler F, Desta-Tsedu N, Robeva A, Dawson J, Wenner P et al (2001) Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 166:2801–2807

102.

Gill JM, Quisel AM, Rocca PV, Walters DT (2003) Diagnosis of systemic lupus erythematosus. Am Fam Physician 68:2179–2186

103.

Mok CC, Lau CS (2003) Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56:481–490CrossRef

104.

Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P et al (2007) High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 66:208–214CrossRef

105.

Caprio M, Fabbrini E, Isidori AM, Aversa A, Fabbri A (2001) Leptin in reproduction. Trends Endocrinol Metab 12:65–72CrossRef

106.

Garcia-Gonzalez A, Gonzalez-Lopez L, Valera-Gonzalez IC, Cardona-Muñoz EG, Salazar-Paramo M, González-Ortiz M et al (2002) Serum leptin levels in women with systemic lupus erythematosus. Rheumatol Int 22:138–141CrossRef

107.

Ryan MJ, McLemore GR Jr, Hendrix ST (2006) Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension 48:988–993CrossRef

108.

Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y et al (2006) Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol 33:1545–1552

109.

Chung CP, Long AG, Solus JF, Rho YH, Oeser A, Raggi P et al (2009) Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 18:799–806CrossRef

110.

Rovin BH, Song H, Hebert LA, Nadasdy T, Nadasdy G, Birmingham DJ et al (2005) Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int 68:1825–1833CrossRef

111.

Wisłowska M, Rok M, Stepień K, Kuklo-Kowalska A (2008) Serum leptin in systemic lupus erythematosus. Rheumatol Int 28:467–473CrossRef

112.

Härle P, Pongratz G, Weidler C, Büttner R, Schölmerich J, Straub RH (2004) Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 63:809–816CrossRef

113.

Tso TK, Huang HY, Chang CK, Liao YJ, Huang WN (2004) Clinical evaluation of insulin resistance and beta-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus. Clin Rheumatol 23:416–420CrossRef

114.

Almehed K, d’Elia HF, Bokarewa M, Carlsten H (2008) Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthr Res Ther 10:R15CrossRef

115.

Vadacca M, Margiotta D, Rigon A, Cacciapaglia F, Coppolino G, Amoroso A et al (2009) Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol 36:295–297CrossRef

116.

De Sanctis JB, Zabaleta M, Bianco NE, Garmendia JV, Rivas L (2009) Serum adipokine levels in patients with systemic lupus erythematosus. Autoimmunity 42:272–274CrossRef

117.

Daniels TE (1996) Sjogren’s syndrome: clinical spectrum and current diagnostic controversies. Adv Dent Res 10:3–8CrossRef

118.

Toussirot E, Gaugler B, Bouhaddi M, Nguyen NU, Saas P, Dumoulin G (2010) Elevated adiponectin serum levels in women with systemic autoimmune diseases. Mediat Inflamm 2010:938408

119.

Katsiougiannis S, Kapsogeorgou EK, Manoussakis MN, Skopouli FN (2006) Salivary gland epithelial cells: a new source of the immunoregulatory hormone adiponectin. Arthr Rheum 54:2295–2299CrossRef

120.

Boström EA, d’Elia HF, Dahlgren U, Simark-Mattsson C, Hasséus B, Carlsten H et al (2008) Salivary resistin reflects local inflammation in Sjögren’s syndrome. J Rheumatol 35:2005–2011

121.

Katsiougiannis S, Tenta R, Skopouli FN (2010) Activation of AMP-activated protein kinase by adiponectin rescues salivary gland epithelial cells from spontaneous and interferon-gamma-induced apoptosis. Arthr Rheum 62:414–419

122.

Sari I, Demir T, Kozaci LD, Akar S, Kavak T, Birlik M et al (2007) Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol 26:1427–1432CrossRef

123.

Toussirot E, Streit G, Nguyen NU, Dumoulin G, Le Huédé G, Saas P, Wendling D (2007) Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 56:1383–1389CrossRef

124.

Park MC, Lee SW, Choi ST, Park YB, Lee SK (2007) Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36:101–106CrossRef

125.

Kotulska A, Kucharz EJ, Brzezińska-Wcisło L, Wadas U (2001) A decreased serum leptin level in patients with systemic sclerosis. Clin Rheumatol 20:300–302CrossRef

126.

Arakawa H, Jinnin M, Muchemwa FC, Makino T, Kajihara I, Makino K, Honda N, Sakai K, Fukushima S, Ihn H (2011) Adiponectinexpression is decreased in the involvedskin and sera of diffuse cutaneous scleroderma patients. Exp Dermatol 20:764–766CrossRef

127.

Popa C, Netea MG, de Graaf J, van den Hoogen FH, Radstake TR, Toenhake-Dijkstra H et al (2009) Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol 36:724–730CrossRef

128.

Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN (2009) Effects of a 6-month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis. Fundam Clin Pharmacol 23:595–600CrossRef

129.

Härle P, Sarzi-Puttini P, Cutolo M, Straub RH (2006) No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 65:970–971CrossRef

130.

Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR et al (2009) Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 27:222–228

131.

Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, De Matias JM et al (2008) Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 26:311–316

132.

Nagashima T, Okubo-Fornbacher H, Aoki Y, Kamata Y, Kimura H, Kamimura T et al (2008) Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. J Rheumatol 35:936–938

133.

Zhang C, Xu X, Potter BJ, Wang W, Kuo L, Michael L et al (2006) TNF-α contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 26:475–480CrossRef

134.

Iliopoulos D, Malizos KN, Tsezou A (2007) Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention. Ann Rheum Dis 66:1616–1621CrossRef

135.

Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M et al (2008) Pharmacological inhibition of nicotinamide phosphoribosyl transferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 3:e2267CrossRef

136.

Senolt L, Housa D, Vernerová Z, Jirásek T, Svobodová R, Veigl D, Anderlová K, Müller-Ladner U, Pavelka K, Haluzík M (2007) Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 66:458–463CrossRef

Title: The role of adipokines in connective tissue diseases
Authors: Robert Krysiak
Gabriela Handzlik-Orlik
Boguslaw Okopien
Publication date: 01-08-2012
Publisher: Springer-Verlag
Published in: European Journal of Nutrition / Issue 5/2012
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-012-0370-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The role of adipokines in connective tissue diseases

Abstract

Objective

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2012

Short-term supplementation with Aronia melanocarpa extract improves platelet aggregation, clotting, and fibrinolysis in patients with metabolic syndrome

Serum and lipoprotein sitostanol and non-cholesterol sterols after an acute dose of plant stanol ester on its long-term consumption

Four-week ingestion of blood orange juice results in measurable anthocyanin urinary levels but does not affect cellular markers related to cardiovascular risk: a randomized cross-over study in healthy volunteers

Aronia melanocarpa fruit extract exhibits anti-inflammatory activity in human aortic endothelial cells

Quercetin regulates organic ion transporter and uromodulin expression and improves renal function in hyperuricemic mice

A sodium-bicarbonated mineral water reduces gallbladder emptying and postprandial lipaemia: A randomised four-way crossover study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page